Comparison of Efficacy Between Thermal Pulsatile System (Lipiflow®) And Conventional Lid Hygiene In Anti-Glaucoma Agent Related Meibomian Gland Dysfunctio
Phase 4
Completed
- Conditions
- glaucoma patientsLipiflowmeibomian gland dysfunctiontopical glaucoma medication
- Registration Number
- TCTR20150919001
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1.Age more than 18 years old
2.Prescribed with one or more topical anti-glaucoma medications in both eyes
3.Diagnosed with MGD stage II or stage III
Exclusion Criteria
1.Blindness or have one eye
2.Underwent trabeculectomy procedure
3.Have advance glaucoma or uncontrolled IOP
4.Have history of ocular surgery or injury within prior 3 months
5.Have history of ocular herpes within prior 3 months
6.Have active ocular inflammation or infection
7.Have eyelid or ocular surface abnormalities
8.Diagnoses with systemic disease causing dry eye
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method meibomian gland expressibility 1 week, 1 month, 3 month, 6 month after intervention meibomian gland express score
- Secondary Outcome Measures
Name Time Method Dry eye symptoms 1 week, 1 month, 3 month, 6 month after intervention interview with questionnaire OSDI score,Tear film stability 1 week, 1 month, 3 month, 6 month after intervention slit lamp examination with tear break up time test,Corneal surface 1 week, 1 month, 3 month, 6 month after intervention Slit lamp examination with corneal staining Oxford score,Tear film lipid layer thickness 1 week, 1 month, 3 month, 6 month after intervention measure with Lipiview instrument,Tear production 1 week, 1 month, 3 month, 6 month after intervention Schirmer's test,meibomian gland drop out 1 week, 1 month, 3 month, 6 month after intervention using meibography